Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma

Nader N. Massarweh, James O. Park, Jordi Bruix, Raymond S.W. Yeung, Ruth Etzioni, Rebecca Gaston Symons, Laura Mae Baldwin, David R. Flum

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: Diagnostic imaging is effective for evaluating patients suspected of having hepatocellular carcinoma (HCC). Although the diagnosis can be established with imaging alone, diagnostic biopsy may be useful for patients with tumors measuring 1 to 2 cm. To date, biopsy and imaging use among patients with HCC has not been evaluated in the general community. Patients and Methods: This cohort study used Surveillance, Epidemiology, and End Results (SEER) -Medicare data (2002- 2005) evaluating biopsy, imaging modalities (ultrasound, computed tomography [CT] scan, and/or magnetic resonance imaging [MRI]), and HCC risk factors. Results: Of 3,696 patients, 1,197 (32.4%) underwent one or more biopsies, with no change in yearly biopsy rate (trend test,P=.64). Patients with tumors > 5 cm were most likely to receive biopsies (35.3%), with increasing rates of biopsy for larger tumors (P = .001). Patients who received biopsies underwent more imaging than those who did not (P < .001) and were more likely to have an HCC risk factor. Tumor size > 5 cm in the setting of a concurrent HCC risk factor increased the odds of biopsy. In 47.8% of patients, the diagnostic sequence was not consistent with contemporary evidence-based guidelines. Conclusions: Despite widespread availability and use of CT scan and MRI, one third of HCC patients undergo biopsy, suggesting a problem with the performance and/or quality of diagnostic imaging or that providers do not believe imaging alone is sufficient to establish the diagnosis. Understanding factors that drive biopsy use may help improve the care of patients with HCC.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalJournal of oncology practice
Volume7
Issue number3
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Diagnostic Imaging
Medicare
Hepatocellular Carcinoma
Biopsy
Tomography
Magnetic Resonance Imaging
Neoplasms
Ultrasonography
Patient Care
Epidemiology
Cohort Studies
Guidelines

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Massarweh, N. N., Park, J. O., Bruix, J., Yeung, R. S. W., Etzioni, R., Symons, R. G., ... Flum, D. R. (2011). Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. Journal of oncology practice, 7(3), 155-160. https://doi.org/10.1200/JOP.2010.000116

Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. / Massarweh, Nader N.; Park, James O.; Bruix, Jordi; Yeung, Raymond S.W.; Etzioni, Ruth; Symons, Rebecca Gaston; Baldwin, Laura Mae; Flum, David R.

In: Journal of oncology practice, Vol. 7, No. 3, 01.05.2011, p. 155-160.

Research output: Contribution to journalArticle

Massarweh, NN, Park, JO, Bruix, J, Yeung, RSW, Etzioni, R, Symons, RG, Baldwin, LM & Flum, DR 2011, 'Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma', Journal of oncology practice, vol. 7, no. 3, pp. 155-160. https://doi.org/10.1200/JOP.2010.000116
Massarweh, Nader N. ; Park, James O. ; Bruix, Jordi ; Yeung, Raymond S.W. ; Etzioni, Ruth ; Symons, Rebecca Gaston ; Baldwin, Laura Mae ; Flum, David R. / Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. In: Journal of oncology practice. 2011 ; Vol. 7, No. 3. pp. 155-160.
@article{45f30a256ece4677a48dfd5ba64c1a0e,
title = "Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma",
abstract = "Purpose: Diagnostic imaging is effective for evaluating patients suspected of having hepatocellular carcinoma (HCC). Although the diagnosis can be established with imaging alone, diagnostic biopsy may be useful for patients with tumors measuring 1 to 2 cm. To date, biopsy and imaging use among patients with HCC has not been evaluated in the general community. Patients and Methods: This cohort study used Surveillance, Epidemiology, and End Results (SEER) -Medicare data (2002- 2005) evaluating biopsy, imaging modalities (ultrasound, computed tomography [CT] scan, and/or magnetic resonance imaging [MRI]), and HCC risk factors. Results: Of 3,696 patients, 1,197 (32.4{\%}) underwent one or more biopsies, with no change in yearly biopsy rate (trend test,P=.64). Patients with tumors > 5 cm were most likely to receive biopsies (35.3{\%}), with increasing rates of biopsy for larger tumors (P = .001). Patients who received biopsies underwent more imaging than those who did not (P < .001) and were more likely to have an HCC risk factor. Tumor size > 5 cm in the setting of a concurrent HCC risk factor increased the odds of biopsy. In 47.8{\%} of patients, the diagnostic sequence was not consistent with contemporary evidence-based guidelines. Conclusions: Despite widespread availability and use of CT scan and MRI, one third of HCC patients undergo biopsy, suggesting a problem with the performance and/or quality of diagnostic imaging or that providers do not believe imaging alone is sufficient to establish the diagnosis. Understanding factors that drive biopsy use may help improve the care of patients with HCC.",
author = "Massarweh, {Nader N.} and Park, {James O.} and Jordi Bruix and Yeung, {Raymond S.W.} and Ruth Etzioni and Symons, {Rebecca Gaston} and Baldwin, {Laura Mae} and Flum, {David R.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1200/JOP.2010.000116",
language = "English (US)",
volume = "7",
pages = "155--160",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma

AU - Massarweh, Nader N.

AU - Park, James O.

AU - Bruix, Jordi

AU - Yeung, Raymond S.W.

AU - Etzioni, Ruth

AU - Symons, Rebecca Gaston

AU - Baldwin, Laura Mae

AU - Flum, David R.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Purpose: Diagnostic imaging is effective for evaluating patients suspected of having hepatocellular carcinoma (HCC). Although the diagnosis can be established with imaging alone, diagnostic biopsy may be useful for patients with tumors measuring 1 to 2 cm. To date, biopsy and imaging use among patients with HCC has not been evaluated in the general community. Patients and Methods: This cohort study used Surveillance, Epidemiology, and End Results (SEER) -Medicare data (2002- 2005) evaluating biopsy, imaging modalities (ultrasound, computed tomography [CT] scan, and/or magnetic resonance imaging [MRI]), and HCC risk factors. Results: Of 3,696 patients, 1,197 (32.4%) underwent one or more biopsies, with no change in yearly biopsy rate (trend test,P=.64). Patients with tumors > 5 cm were most likely to receive biopsies (35.3%), with increasing rates of biopsy for larger tumors (P = .001). Patients who received biopsies underwent more imaging than those who did not (P < .001) and were more likely to have an HCC risk factor. Tumor size > 5 cm in the setting of a concurrent HCC risk factor increased the odds of biopsy. In 47.8% of patients, the diagnostic sequence was not consistent with contemporary evidence-based guidelines. Conclusions: Despite widespread availability and use of CT scan and MRI, one third of HCC patients undergo biopsy, suggesting a problem with the performance and/or quality of diagnostic imaging or that providers do not believe imaging alone is sufficient to establish the diagnosis. Understanding factors that drive biopsy use may help improve the care of patients with HCC.

AB - Purpose: Diagnostic imaging is effective for evaluating patients suspected of having hepatocellular carcinoma (HCC). Although the diagnosis can be established with imaging alone, diagnostic biopsy may be useful for patients with tumors measuring 1 to 2 cm. To date, biopsy and imaging use among patients with HCC has not been evaluated in the general community. Patients and Methods: This cohort study used Surveillance, Epidemiology, and End Results (SEER) -Medicare data (2002- 2005) evaluating biopsy, imaging modalities (ultrasound, computed tomography [CT] scan, and/or magnetic resonance imaging [MRI]), and HCC risk factors. Results: Of 3,696 patients, 1,197 (32.4%) underwent one or more biopsies, with no change in yearly biopsy rate (trend test,P=.64). Patients with tumors > 5 cm were most likely to receive biopsies (35.3%), with increasing rates of biopsy for larger tumors (P = .001). Patients who received biopsies underwent more imaging than those who did not (P < .001) and were more likely to have an HCC risk factor. Tumor size > 5 cm in the setting of a concurrent HCC risk factor increased the odds of biopsy. In 47.8% of patients, the diagnostic sequence was not consistent with contemporary evidence-based guidelines. Conclusions: Despite widespread availability and use of CT scan and MRI, one third of HCC patients undergo biopsy, suggesting a problem with the performance and/or quality of diagnostic imaging or that providers do not believe imaging alone is sufficient to establish the diagnosis. Understanding factors that drive biopsy use may help improve the care of patients with HCC.

UR - http://www.scopus.com/inward/record.url?scp=80052718551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052718551&partnerID=8YFLogxK

U2 - 10.1200/JOP.2010.000116

DO - 10.1200/JOP.2010.000116

M3 - Article

C2 - 21886495

AN - SCOPUS:80052718551

VL - 7

SP - 155

EP - 160

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 3

ER -